ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
The program will leverage BioStrand's LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio's Multifunctional Polymeric Nanocapsules (MPN Technology®) The Alliance has
United States Dennis Riedl Libera Bio Olivier Jarry Talem Therapeutics Company Annual Information Form
Source: finanznachrichten.de